市场调查报告书
商品编码
1521301
2024-2032 年按产品类型(分析仪、消耗品)、模式(台式、便携式)、最终用户(医院、诊所、门诊手术中心等)和地区分類的血气和电解质分析仪市场报告Blood Gas and Electrolyte Analyzer Market Report by Product Type (Analyzers, Consumables), Modality (Benchtop, Portable), End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region 2024-2032 |
IMARC Group年,全球血气及电解质分析仪市场规模达21亿美元。
血气和电解质分析仪是指用于测量全血样本中各种参数的医疗设备,包括血气(二氧化碳和氧气的分压)、pH、电解质和代谢物。它们广泛用于检测代谢失衡以及测量肾臟和心臟功能。它们还有助于确定血液中异常的电解质水平、氧气或二氧化碳交换水平以及患者的酸碱平衡。此外,它们还有助于识别糖尿病、血管出血和药物消耗。近年来,血液气体和电解质分析仪因其易用性、成本效益、准确性和快速结果而在临床诊断实验室和重症监护病房中广受欢迎。
血液气体和电解质分析仪可以简化工作流程,最大限度地减少错误,需要最少的维护,并快速提供准确的结果。因此,重症监护病房(ICU)、手术室和急诊科的患者数量不断增加是推动市场成长的主要因素。除此之外,糖尿病和心血管疾病等慢性疾病的广泛流行,以及更容易患这些疾病的老年人口的不断增加,都增加了产品需求。此外,对高吞吐量、整合和自动化系统的需求也显着增加。同时,血气和电解质分析仪与实验室资讯系统和电子病历的不断集成,以简化工作流程并能够有效监测患者健康状况,正在促进市场成长。此外,一些领先的参与者正在大力投资开发便携式血气和电解质分析仪,这些分析仪具有易于使用和操作的特性以及最低的维护要求。其他因素,包括对即时检测 (POCT) 偏好的转变、医疗保健行业的发展、技术进步、产品创新以及广泛的研发 (R&D) 活动,也正在创造有利的市场前景。
The global blood gas and electrolyte analyzer market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.
Blood gas and electrolyte analyzers refer to medical devices used to measure various parameters, including blood gas (partial pressure of carbon dioxide and oxygen), pH, electrolytes, and metabolites, in a whole blood sample. They are widely utilized for the detection of metabolic imbalances and the measurement of renal and cardiac functions. They also help determine abnormal electrolyte levels in the blood, levels of oxygen or carbon dioxide exchange, and the acid-base balance of the patient. Moreover, they assist in identifying diabetes, blood vessel hemorrhage, and drug consumption. In recent years, blood gas and electrolyte analyzers have gained immense popularity across clinical diagnostic labs and critical care units due to their ease of use, cost-effectiveness, accuracy, and fast results.
Blood gas and electrolyte analyzers can streamline work processes, minimize errors, require minimum maintenance, and provide accurate results quickly. As a result, the increasing number of patients in intensive care units (ICUs), operating rooms, and emergency departments represent the primary factor driving the market growth. Besides this, the widespread prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the growing geriatric population that is more susceptible to developing these medical ailments are augmenting the product demand. Additionally, there has been a significant increase in the demand for high throughput, integrated, and automated systems. Along with this, the rising integration of blood gas and electrolyte analyzers with laboratory information systems and electronic medical records to streamline the workflow and enable effective monitoring of patient health is catalyzing the market growth. Furthermore, several leading players are making heavy investments for the development of portable blood gas and electrolyte analyzers with easy-to-use and handle features and minimum maintenance requirements. Other factors, including the shifting preferences toward point-of-care testing (POCT), developments in the healthcare industry, technological advancements, product innovations, and extensive research and development (R&D) activities, are also creating a favorable market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood gas and electrolyte analyzer market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, modality and end user.
Analyzers
Consumables
Benchtop
Portable
Hospitals
Clinics
Ambulatory Surgical Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.